Daridorexant
| Daridorexant | |
|---|---|
| Salts [] | |
|---|---|
| Daridorexant hydrochloride | |
| Molecular structure via molpic based on CDK |
| Physical properties [] | |
|---|---|
| Molecular mass | 450.9 g/mol [1] |
| Predicted LogP | 4.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C23H23ClN6O2 [1] |
| IUPAC name | [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone [1] |
| SMILES | CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl [1] |
| InChI | InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1 [1] |
| InChIKey | NBGABHGMJVIVBW-QHCPKHFHSA-N [1] |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 8 hours (6 – 10 hours)[6] |
| Duration of action | ~8 hours (50 mg) |
Daridorexant (also known as Nemorexant, ACT-541468, Quviviq, Dea no. 2410, Methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-, daridorexantum, ((2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)-(5-methoxy-2-(triazol-2-yl)phenyl)methanone, Dtxcid901766549, ((S)-(2-(5-chloro-4-methyl-1H-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl) (5 methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone) or 5-chloro-2-((2S)-1-(5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-methylpyrrolidin-2-yl)-4-methyl-1H-1,3-benzodiazole) is a
Chemistry
Salts []
Daridorexant is typically found in the form of its hydrochloride salt.
Stereochemistry []
Daridorexant is a absolute mixture.
Pharmacology
ATC Classification
In the nervous system (N) daridorexant acts as a daridorexant (N05CJ03), hypnotics and sedative (N05C), orexin receptor antagonist (N05CJ) and psycholeptic (N05).[1]Subjective effects []
| emily / Daridorexant [] | |
|---|---|
Routes:
| |
| Pilz / Daridorexant [] | |
|---|---|
Routes:
| |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 91801202, Daridorexant. Accessed August 10, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/91801202
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Daridorexant. UNII: LMQ24G57E9. Global Substance Registration System. Accessed August 10, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/LMQ24G57E9
Summary Basis of Decision for Quviviq. August 4, 2023. Accessed August 10, 2026. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1691500592141
Details for: Quviviq. September 8, 2023. Accessed August 10, 2026. https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102615
Daridorexant Medicinal forms. The National Institute for Health and Care Excellence (NICE). Accessed August 10, 2026. https://bnf.nice.org.uk/drugs/daridorexant/medicinal-forms/
Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology. November 1, 2020; 16(11):1063–1078.